26348-70-9

Basic information

• Product Name: Methyl L-lysinate dihydrochloride
• Synonyms: H-LYS-OME;H-LYS-OME 2HCL;METHYL (S)-2,6-DIAMINOHEXANOIC ACID DIHYDROCHLORIDE;L-LYSINE METHYL ESTER DIHCL;L-LYSINE METHYL ESTER DIHYDROCHLORIDE;L-LYSINE METHYL ESTER DIHYDROCHLORIDE SALT;L-LYSINE METHYL ESTER HYDROCHLORIDE;LYSINE-OME 2 HCL
• CAS NO: 26348-70-9
• Molecular Formula: C₇H₁₇N₂O₂*Cl
• Molecular Weight: 233.14
• EINECS: 247-625-7
• Product Categories: Amino Acid Derivatives;Amino Acids;Lysine [Lys, K];Amino Acids and Derivatives;Amino Acid Methyl Esters;Amino Acids (C-Protected);Biochemistry;Amino hydrochloride;Amino Acids;I - Z;Modified Amino Acids;Amino Acids & Derivatives
• Mol File: 26348-70-9.mol
• Article Data: 31

Chemical Properties

• Melting Point: 213-215°C
• Boiling Point: 243.9 °C at 760 mmHg
• Flash Point: 93.5 °C
• Appearance: White/Crystalline Powder
• Density: 1.031 g/cm³
• Vapor Pressure: 0.0313mmHg at 25°C
• Refractive Index: 17 ° (C=5, H2O)
• Storage Temp.: −20°C
• Solubility: Methanol, Water
• Water Solubility: Soluble in water.
• Sensitive: Hygroscopic
• BRN: 5302183
• CAS DataBase Reference: Methyl L-lysinate dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl L-lysinate dihydrochloride(26348-70-9)
• EPA Substance Registry System: Methyl L-lysinate dihydrochloride(26348-70-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39-24/25
• WGK Germany: 3
• Hazardous Substances Data: 26348-70-9(Hazardous Substances Data)

Usage

Description

Methyl L-lysinate dihydrochloride, also known as L-Lysine methyl ester dihydrochloride, is a light yellow solid with unique chemical properties. It is a derivative of the amino acid L-lysine, where the carboxylic acid group is esterified with a methyl group and the compound is then treated with hydrochloric acid to form the dihydrochloride salt.

Uses

Used in Pharmaceutical Industry:
Methyl L-lysinate dihydrochloride is used as a building block for the synthesis of peptides containing histidine and lysine. These synthesized peptides have potential applications in the development of drugs targeting various medical conditions.
Used in Chemical and Material Science Industry:
Methyl L-lysinate dihydrochloride is used as a precursor in the production of lysine methyl ester-based cationic surfactants and hydrogels. These surfactants and hydrogels have a wide range of applications, including detergents, personal care products, and biomedical materials.

InChI:InChI=1/C7H16N2O2/c1-11-7(10)6(9)4-2-3-5-8/h6H,2-5,8-9H2,1H3/p+2/t6-/m0/s1

Upstream product

• 67-56-1 methanol 
• 56-87-1 L-lysine 
• 657-27-2 L-Lysine hydrochloride 
• 77-76-9 2,2-dimethoxy-propane 
• 75-77-4 chloro-trimethyl-silane 
• 70-53-1 2,6-diaminohexanoic acid hydrochloride 
• 26124-78-7 (S)-α-lysine hydrochloride 
• 13734-28-6 Boc-Lys-OH 
• 17929-90-7 3-aminoazepan-2-one 

Downstream Products

• 943590-99-6 C₂₃H₂₉N₃O₅ 
• 139091-49-9 (3R)-AH(Nps)IBA-L-Lys 
• 139091-49-9 (2S,3S)-AH(Nps)IBA-L-Lys 
• 139091-49-9 (2R,3S)-AH(Nps)IBA-L-Lys 
• 943443-86-5 C₂₂H₃₃N₄O₆ 
• 1197285-78-1 (S)-2-{(2R,3R,Z)-1-[(S)-2-benzamido-6-guanidinohexanoyl]-4-ethylidene-3-methylpyrrolidine-2-carboxamido}-4-methyl-pentanoic acid 
• 1337555-97-1 (S)-2-{(2R,3S,Z)-1-[(S)-2-benzamido-6-guanidinohexanoyl]-4-ethylidene-3-methylpyrrolidine-2-carboxamido}-4-methyl-pentanoic acid 
• 1337556-02-1 (S)-2-{(2S,3S,Z)-1-[(S)-2-benzamido-6-guanidinohexanoyl]-4-ethylidene-3-methylpyrrolidine-2-carboxamido}-4-methyl-pentanoic acid 
• 1360186-70-4 (S)-methyl 2-((2S,3R,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methylpentanoate 
• 1360186-73-7 (S)-methyl 2-((2S,3S,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methyl pentanoate 
• 1360186-75-9 (S)-methyl 2-((2R,3S,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methylpentanoate 
• 1360186-79-3 (S)-methyl 2-((2R,3R,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methylpentanoate 
• 1197285-64-5 (S,Z)-methyl 2-benzamido-6-(2,3-bis(tert-butoxycarbonyl)guanidino)hexanoate 
• 1197285-65-6 (S,Z)-2-benzamido-6-(2,3-bis(tert-butoxycarbonyl)guanidino)hexanoic acid 

Relevant articles and documents

Understanding the binding properties of phosphorylated glycoluril-derived molecular tweezers and selective nanomolar binding of natural polyamines in aqueous solution

A modular synthetic platform for the construction of flexible glycoluril-derived molecular tweezers was developed. The binding properties of four exemplary supramolecular hosts obtained via this approach towards 16 organic amines were investigated by means of 1H NMR titration. In this work, we compare the Ka values obtained this way with those of three structurally related molecular tweezers and provide a computational approach towards an explanation of the observed behavior of those novel hosts. The results showcase that certain structural modifications lead to very potent and selective binders of natural polyamines, with observed binding of spermine below 10 nM. This journal is

Novel chiral derivatizing agents for 1H NMR determination of enantiomeric purities of carboxylic acids

(S)-4-(3-Aminopyrrolidin-1-yl)coumarin (1), (S)-4-(3-aminopiperidin-1-yl)coumarin (4), and (S)-4-(3-aminoazepan-1-yl)coumarin (7), prepared from 4-chlorocoumarin and (S)-pyrrolidin-3-amine, (S)-piperidin-3-amine, and (S)-azepan-3-amine, respectively, were proven to be versatile and reliable 1H NMR optical purity determination agents for chiral carboxylic acids.

NOVEL DRUG DELIVERY CONJUGATED MOIETY FOR ORAL ADMINISTRATION OF DRUG UNSUITABLE FOR ORAL ADMINISTRATION AND PREPARATION METHOD THEREOF

The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof is combined with a drug, which is not suitable for oral administration, and is administered orally, it exhibits an excellent absorption rate without decreasing the biological activities of the drug. Moreover, the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof can be easily prepared in a few steps, which is very advantageous in terms of mass production.